Waverley Pharma Inc. is a specialty pharma company that is dedicated to the development and commercialization of safe, effective and affordable therapeutics. The company’s current focus is on the generic oncology market in the United Kingdom (U.K.) and North America. The company has five generic oncology products on the U.K. market, and is awaiting regulatory approval of four additional oncology generics for the U.K. and North American markets. The company is currently a pipeline of products in different stages of development, through multiple partnerships. Waverley Pharma is committed to providing patients with affordable prescription medicines that lower healthcare costs and provide a better quality of life.
Mr. Thiessen joined Waverley Pharma in February 2020. He has extensive pharmaceutical experience having worked for Bausch Health Companies Inc. (formerly Biovail Corporation), for 28 years, working his way up from manager to site director of the manufacturing operation in Steinbach, Manitoba. He led a team of roughly 400 employees and provided overall leadership and strategic direction at the operation. Mr. Thiessen has a Bachelor of Science in Biology and an Executive M.B.A. from Athabasca University in Edmonton, Alberta.
Mr. Uddin has been the senior financial analyst at Waverley Pharma since August 2019. Previously, he worked at Ernst & Young as a senior accountant in assurance services. Mr. Uddin has significant experience working with life science companies in both Canada and the United States and spent time in both Houston, Texas and San Francisco, California working with clients. He has a Bachelor of Commerce (Hons.) degree from the University of Manitoba and is a Chartered Professional Accountant.